PaxMedica rises on research agreement with PoloMar Health

Kuvatris Therapeutics

08/06/2023 19:26

** Shares of biopharmaceutical co PaxMedica Inc  PXMD.O  up
as much as 14.5% at $1.50 
    ** Co enters research collaboration deal with PoloMar Health
for phase II study in autism spectrum disorder 
    ** Adds that deal is to investigate use of emodin in a
clinical program as potential treatment for patients with autism
spectrum disorder
    ** PXMD expects phase II proof-of-concept trial to begin in
Q2 of 2023
    ** Including session gains, stock has fallen 26% YTD 

 (Reporting by Amna Karimi in Bengaluru)
 ((Amna.Karimi@thomsonreuters.com; +91 8083261226;))